Infantile spasms are characterized by age-specific expression of epileptic spasms and hypsarrhythmia and often result in significant cognitive impairment. Other epilepsies or autism often ensue especially in symptomatic IS (SIS). Cortical or subcortical damage, including white matter, have been implicated in the pathogenesis of SIS. To generate a model of SIS, we recreated this pathology by injecting rats with lipopolysaccharide and doxorubicin intracerebrally at postnatal day (P) 3 and with p-chlorophenylalanine intraperitoneally at P5. Spasms occurred between P4 and 13 and were associated with ictal EEG correlates, interictal EEG abnormalities and neurodevelopmental decline. After P9 other seizures, deficits in learning and memory, and autistic-like behaviors (indifference to other rats, increased grooming) were observed. Adrenocorticotropic hormone (ACTH) did not affect spasms. Vigabatrin transiently suppressed spasms at P5. This new model of SIS will be useful to study the neurobiology and treatment of SIS, including those that are refractory to ACTH.
Introduction
The infantile spasms (IS) syndrome is an age-related epileptic disorder characterized by spasms and hypsarrhythmia, described as high amplitude multifocal epileptiform discharges on a disorganized background (Hrachovy and Frost, 2003) . Ictal correlates include the electrodecremental response but can be variable (Kellaway et al., 1979) . The emergence of the spasms is often associated with developmental decline that may improve if spasms are treated effectively (Caplan et al., 2002; Goh et al., 2005) . Many patients with IS eventually develop other intractable epilepsy syndromes (Rantala and Putkonen, 1999) , mental retardation (Riikonen, 1982; Riikonen and Amnell, 1981) and autistic features (Rantala and Putkonen, 1999; Riikonen and Amnell, 1981) leading to lifelong debilitation. Under the current International League Against Epilepsy classification, IS are classified into symptomatic, cryptogenic and idiopathic (Watanabe, 1998) . Symptomatic IS (SIS) result from preexisting brain disorders, often multifocal pathology, and comprise the largest proportion of cases (Hrachovy and Frost, 2003; Watanabe, 1998) . Multiple etiologies have been described, often as a combination of additive insults (Watanabe, 1998) . In cryptogenic IS, a central nervous system dysfunction is suspected but remains unidentified 8 . In idiopathic cases the cause is suspected to be genetic.
IS are refractory to most conventional antiepileptic drugs. The recommended first line therapies are adrenocorticotropic hormone (ACTH) and, in patients with IS due to tuberous sclerosis, vigabatrin. ACTH and vigabatrin are not always effective and may have potentially severe side effects (Mackay et al., 2004 ). The prognosis is better when treatments are effective in controlling IS and even patients with SIS may not regress and continue to acquire developmental milestones at a rate determined by the underlying etiology (Caplan et al., 2002; Goh et al., 2005; Primec et al., 2006) . For this purpose, it is crucial to develop successful animal models of SIS to study mechanisms and design more safe and effective treatments. Here we describe an animal model of SIS that satisfies many of the criteria for a successful model of the IS syndrome (Stafstrom et al., 2006) . This model was developed based on evidence that structural or functional abnormalities in cortical or subcortical structures or 
